Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 349 clinical trials
Featured trial
Albuterol in Patients With Lymphangioleiomyomatosis

to block the flow of air. It is a progressive disease, and in severe cases may require a lung transplant. One possible treatment to improve breathing in people with LAM is inhaled albuterol. Albuterol

  • 22 Dec, 2020
  • 1 location
Featured trial
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that becomes worse over time. There is currently no effective treatment for it. Researchers want to study the disease and learn new ways to treat it. Objectives: To discover new pathways that are involved in pulmonary fibrosis. To develop new …

ct scan
chest x-ray
chest ct
idiopathic pulmonary fibrosis
  • 23 Nov, 2020
  • 1 location
Featured trial
A phase II study of Antineoplastons A10 And AS2-1 Private In Children With Primary Malignant Brain Tumors

A phase II study of Antineoplastons A10 And AS2-1 Private In Children With Primary Malignant Brain Tumors

  • 08 Nov, 2020
  • 1 location
Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases

-administer oral entrectinib or crizotinib as described in the protocol and local prescribing information. Treatments will continue until progressive disease, unacceptable toxicity, death, or withdrawal from

progressive disease
cancer chemotherapy
systemic therapy
proto-oncogene tyrosine-protein kinase ros
  • 21 Sep, 2022
  • 48 locations
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)

The purpose of the study is to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a particular type of lung cancer. This type of cancer is called non-small …

cancer chemotherapy
systemic therapy
lung carcinoma
epidermal growth factor receptor
  • 06 Jun, 2022
  • 60 locations
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

  • 20 Jun, 2022
  • 1 location
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant …

  • 07 Apr, 2022
  • 136 locations
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis (PROGRESSION)

Idiopathic pulmonary fibrosis (IPF) is a prototype of chronic, progressive, and fibrotic lung disease. It has been considered rare, with an incidence estimated to 11.5 cases per 100 000 individuals per year. Increasing rates of hospital admissions and deaths due to IPF suggest an increasing burden of disease. The median …

  • 24 Mar, 2022
  • 9 locations
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy (AERN)

in rrHL, nevertheless CR-rates are low and a considerable proportion of patients suffers from progressive disease. Localized RT induces an immunogenic effect which might work synergistically and

  • 04 Oct, 2022
  • 1 location
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

doses of LAE001/prednisone and afuresertib in m-CRPC patients who have progressive disease or are intolerant of 2 prior standard treatments of any anti-androgen or anti-androgen treatment plus

other therapies
androgen suppression
gilbert's syndrome
  • 04 Oct, 2022
  • 17 locations